Authors Posts by Joshua Rodriguez

Joshua Rodriguez

2633 POSTS 445 COMMENTS
Hey everyone, I'm Joshua Rodriguez. I'm the founder of CNA Finance as well as several other sites. If you'd like to connect with me, follow me on or Twitter! I'd love to see ya there. Also, if you're looking for top quality content for your blog, news outlet, or any other website for that matter, please reach out to me at Info@CNAFin.com! Legal Disclaimer - CNA Finance is NOT an investment advisor. All investment decisions should be well thought out and made with the help of a an investment advisor. For our full legal disclaimer, please scroll to the bottom right of this page.

MRK Stock News

MRK Stock NewsGilead Sciences, Inc. (NASDAQ: GILD) | AbbVie Inc (NYSE: ABBV)

Gilead Sciences and AbbVie Inc play a major role in the Hepatitis C Virus treatment market. The combination of Sovaldi, Harvoni (GILD) and Viekira (ABBV) is not only incredibly effective in treating the virus, the combination is the market leader around the world. Considering the facts that hepatitis C affects a mass amount of people, and that treatments are relatively pricey; the combination treatment naturally brings in mass amounts of money for both companies.

Merck & Co., Inc. (NYSE: MRK)

On the other hand, Merck & Co. is working on its own entry into the hepatitis C treatment market. As a matter of fact, tomorrow the European Association for the Study of the Liver is expected to release abstracts. Within the release, we should see Phase III data for Merck’s combination to be announced; a combination that is directly in competition with the GILD, ABBV combination treatment. This is huge news because in Phase II, MRK’s cure rates were in line with the GILD, ABBV combination.

What We’re Likely To See From GILD, ABBV, And MRK Tomorrow

  • Gilead Sciences/AbbVie Inc – I’m expecting to see both of these stocks hit a bump in the road tomorrow and take a turn to downtrends. While I don’t expect the downtrends to last, with expectations of Merck & Co.’s Phase III data to be released and be just as strong as Phase II, the market is going to react to new competition in the hepatitis C virus treatment space getting closer to launch.
  • Merck & Co. – On the other hand, I’m expecting to see great things from Merck & Co. stock tomorrow. If Phase III data is released, and it is as good as analysts are expecting it to be, we can expect to see a major rally in this one tomorrow; so, get ready for the break out.

What Do You Think?

Do you think we’ll see Phase III data from MRK? Will it cause a breakout? How do you think tomorrow’s release may affect GILD and ABBV? Let us know in the comments below!

DYAX Corp. Stock News

DYAX Corp. Stock NewsDyax Corp. (NASDAQ: DYAX)

Dyax stock has had an amazing week in the market. After climbing more than 40% on April 1st, the stock has continued the upward momentum. So, a couple big questions are starting to pop up. “Why is DYAX climbing so much?” and “Will the upward momentum continue?” Let’s take a look and find out!

Why DYAX Is Up

There are a couple of reasons that DYAX is climbing at the moment…

  • Early Angioedema Drug Results – Early testing of Dyax Corp.’s new angioedema drug proved to be a hit. As a matter of fact, analysts were throwing around words like “best-in-class” and wondering whether or not DYAX had found a cure. As a result, we saw the 40%+ stock price jump on April 1st.

  • Secondary Offering – Recently, DYAX announced a new public offering of 7 million shares of common stock. They also set an overallotment option for an additional 1.05 million shares to be offered. Overall, these shares will bring a value of more than $230 million considering that the price per share doesn’t move.

Will Dyax Corp. Continue To Grow?

In my opinion, we’re going to see a lot more upward momentum from this one moving forward. The bottom line is that the company has broken ground on a new treatment that looks to be best in class and could eliminate HEA attacks all together for some patients! That’s absolutely amazing. Considering the overwhelming positive results, I’d assume that the next phases of testing will be just as if not more appealing and we’ll see more upward price movement as a result.

Don’t Forget About Small Cap BioTech Volatility

While I do believe that the upward trend is going to continue, I think it’s important that investors and traders remember that when it comes to small cap biotech stocks, we tend to see quite a bit of volatility. So, chances are that this will not be a straight line to the top; we will see declines here and there. Nonetheless, in the long run, this looks to be a great investment option.

What Do You Think?

Do you think DYAX will continue the upward momentum? Let us know in the comments below!

MannKind Stock News

MannKind Stock NewsIn the world of biotech stocks, there are few that are more talked about recently than MannKind and Gilead Sciences. Both companies have made incredible advances in the medical space and are worthy of investment dollars in my opinion. However, there’s always one that will yield better than the other. With that said, let’s take a look to see which is the better long term investment…

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences is an incredible contender in the biotech space. The company has engineered medications that have taken the HIV and Hepatitis C markets by storm; and currently has the controlling market share in the treatment of both of these ailments. As a result, over the past few years, we’ve seen exceptional growth; and since we’re talking about long term, the short term drops we’ve seen recently only mean that we can get in cheap! All in all, GILD is a solid long term investment option.

MannKind Corporation (NASDAQ: MNKD)

MannKind on the other hand has made incredible advances in the world of diabetes. While insulin used to be injected, they’ve come up with an inhaled insulin that, according to physician feedback, seems to be a much more stable option. The difference here is that MannKind’s new insulin, Afrezza, hasn’t yet taken the market by storm. In fact, it’s very new! This in itself lends potential for incredible upward movement as this new, superior insulin takes the market by storm. With that said, MNKD has incredible potential for upward growth.

MNKD or GILD Which Is A Better Long Term Investment?

While I absolutely love GILD as a long term investment option, it’s important to remember that their products are already taking their respective markets by storm and controlling market share. When it comes to MNKD, they have a product that will most likely do the same, but hasn’t done so yet. So, while both MannKind and Gilead Sciences will most likely yield incredible gains over the long run, the chances for exceptional breakouts and larger profits are higher with MannKind.

What Do You Think?

Do you think MNKD or GILD is the better investment? Let us know in the comments below!

Cytori stock news

Cytori stock newsCytori Therapeutics Inc (NASDAQ: CYTX)

Yesterday was an absolutely amazing day in the market for Cytori. After being granted regulatory clearance in China, the stock skyrocketed. Although we did see a bit of a spike in early trading this morning, the rest of the day has shown movement in the downward direction as the market starts to show strong resistance.

Where CYTX Is Meeting Resistance

In this case, the resistance point is clearly at $1.40 per share. Looking back to yesterday, the stock reached this point before falling at 9:30, 1:00, and again at 9:30 this morning. Before it reaches this point, there’s a clear parabolic pattern showing that resistance is on the way as well. Finally, while the stock has reached this point 3 times in the past 2 days, it has still not broken out!

Can We Expect To See A Breakout?

In my opinion, the answer is “Yes”. The investing world is incredibly interesting in the fact that we follow strategies that hinder growth or declines here and there. That’s exactly what we’re doing right now. However, we can’t discount the great news we got yesterday. CYTX got regulatory clearance in China; opening not only a huge market to the company, but the world’s largest health care market! For any health care company, that’s huge news! While it may take some time for the breakout to happen, it’s innevitable moving forward.

What We Can Expect From Cytori Moving Forward

For this one, I decided to ask my friends Jeff and Ross from WarriorTrading.com. If you haven’t checked out their site, take the time and give it a look; the guys are geniuses! With that being said, geniuses are very busy; so, they didn’t have much time, but their answers were very clear…

Jeff – “CYTX we traded last week. It looks like it is having trouble getting through that triple top at 1.47, once it breaks OVER that, it will probably be a nice breakout. if not, it is still trading in a range. Volume pretty light today.”

“Yeah i agree, over $1.50 is of interest, until it breaks it will be light on vol i think”

What Do You Think?

What do you think will happen with CYTX stock? Are we going to see a breakout? Let us know in the comments below!

Sanofi MannKind Afrezza Partnership

Sanofi MannKind Afrezza PartnershipSanofi SA (ADR) (NYSE: SNY)

Sanofi has launched its new Toujeo insulin for diabetics in the United States; and while the launch is expected to be a big hit; however, the company is still headed for a bit of a problem. The current dominant insulin on the market is Sanofi’s Lantus. According to an incredible article on Seeking Alpha, Lantus brought in more than $7 billion last year; driving profitability for the company. Unfortunately, next year, Sanofi’s patent on Lantus will expire; leading to generic choices hitting the market, lower prices, and lower profits! So, what is Sanofi to do? Well…

That’s Where MannKind’s Afrezza Comes In

MannKind Corporation (NASDAQ: MNKD)

If you follow biotech at all, you know about Afrezza. Afrezza is a new inhaled insulin that type 1 diabetics use before meals. Early on, physicians have quite a bit of positive feedback surrounding the drug; leading to an increase in the company’s target price at Jeffries. However, it’s important to remember that MannKind isn’t the only company with their hands in this basket of golden eggs; Sanofi is playing a huge role as well. While Afrezza is created and produced by MannKind, it is licensed to Sanofi with regard to promotion and distribution. This means that as Afrezza becomes the major hit investors, analysts, and other experts expect it to become, gains from Afrezza could offset losses from generic versions of Lantus for Sanofi; leading to maintained revenue and profits!

What To Expect From SNY And MNKD Moving Forward

Moving forward, I’m expecting to see great things out of both companies. However, I do have to say that there is much more potential for growth in MNKD than in SNY in my opinion. While Afrezza will positively affect Sanofi, Lantus will definitely see some losses over the next year or two. However, MannKind has nothing to lose and all to gain; so we should see big long term gains from the stock.

What Do You Think?

Where do you think Sanofi and MannKind are headed? Let us know in the comments below!

Gilead Sciences Stock News

Gilead Sciences Stock NewsGilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences has had a tough month or so in the market. However, in my personal opinion, it’s still a great investment option. As a matter of fact, I would even venture to say that it’s one of the best in biotech. With that said, we’re going to take a look at why we’ve seen downward price movement recently, what we can expect in the near future, and why I believe that GILD stock is a solid investment. So, let’s get right to it.

Why We’ve Seen Recent Declines In GILD Stock

When it comes to any stock, it’s important to remember that any one of a number of factors can play a role in the stock’s value; and that correlation does not always imply causation. With that said, my research points to a couple of key factors causing the drop. Here they are…

  • US Economic Outlook – If you haven’t noticed, US stocks as a whole have had a hard time recently, and I think that has a lot to do with the economy. While the US economy was showing incredible signs of growth throughout 2014, the year 2015 hasn’t been so great; and investors are taking note. With a strong dollar hurting exports and consumers spending less, it’s only natural that we see corrections in the market.

  • Medication Pricing Conversations – One of the biggest conversations in biotech today is the fact that patients, insurance companies, and regulatory agencies alike are all talking about the high cost of medication. This could lead to a change in how medication pricing works and with GILD selling some medications at $1,000 per pill; these conversations could lead to a cut in the company’s revenue.

 

Why GILD Is A Great Investment Option Anyway

Although the US economic outlook may be changing and medication price conversations are active. There are still plenty of reasons to invest in Gilead Sciences.

  • HIV/Hepatitis C Market Share – Gilead Sciences is the world leader when it comes to HIV and Hepatitis C treatments. Even if the cost of the treatments were to decline a bit; with the mass amounts of people affected by these ailments, GILD still stands to make plenty of money in the market.
  • Ask The Analysts – Don’t believe me, just look at what analysts have had to say about GILD lately. Most recently, Vetr upgraded the stock from a “Buy” rating to a “Strong Buy”; and that’s just the most recent in a long list of upgrades dating back to February 3rd.
  • Priced & Positioned For Growth – With the declines we’ve seen over the past month, the price of GILD stock has been driven to a low and we should see support in the charts relatively soon. Looking at what the company does, and how much of the market they control; it’s easy to see that the company will grow. Now, it’s all about getting in at the right price; and since the stock is at a low, now may be the best time!

What Do You Think?

Where do you think GILD is headed and why? Let us know in the comments below!

Herbalife Stock News

Herbalife Stock NewsHerbalife Ltd. (NYSE: HLF)

For some time now, we’ve seen a pretty public battle between Herbalife and activist investor and short seller, Bill Ackman. For quite some time now, Bill Ackman has claimed that Herbalife is nothing more than an illegal pyramid scheme that takes advantage of investors and members. However, the company has maintained its innocence through the onslaught of accusations sent their way by Ackman. Nonetheless, it seems as though Ackman may be onto something. As reported at Investors.com, there is an ongoing federal investigation into the company. As a result, the value of HLF fell hard in morning trading.

The Federal Investigation

According to the report mentioned above, the top 10 sellers at Herbalife were contacted by federal agents last week. While the investigating agency is being kept under wraps at the moment, Herbalife is being very open about the investigation. In a statement, the company told Reuters that it is cooperating with authorities and remains confident in its business practices.

How HLF Stock Reacted

In morning trading today, Herbalife stock fell hard; losing more than 4.5%. However, it seems as though investors have faith in the company’s business practices as well because the stock has made a complete recovery; working it’s way to the green. Currently (11:44), it is trading at $43.17 per share after a slight gain of 0.61% so far today.

What We Can Expect From Herbalife Moving Forward

Moving forward, I think we’ll see growth out of Herbalife. While the federal investigation and Ackman’s arguments may seem like bad news, they are bringing what seemed like a fading company back into the lime light. The reality is that there is an investigation, but chances are that Herbalife isn’t doing anything wrong. So, pretty soon, we can expect the results of the investigation to be positive, the smoke will clear, and we’ll start to realize gains.

What Do You Think?

Where do you think HLF is headed and why? Let us know in the comments below!

Cytori stock news

Cytori stock newsCytori Therapeutics Inc (NASDAQ: CYTX)

CYTX stock is flying high today on positive news from China. The company announced that its exclusive licensee, Lorem Vascular, was granted by the State Food and Drug Administration of the People’s Republic of China. This is huge news for Cytori as China is currently the largest health care market in the world; and now, Cytori’s Celution System will be available in that market.

What This Means For CYTX

This is great news for Cytori Therapeutics. The bottom line is that by making their treatment available in China, their sales have no where to go, but up. Since investors like to see revenue flowing, this means that the current investors are happy, and new investors will be interested as the company continues to show more and more sales.

What We’ve Seen From Cytori Today

Today, Cytori Therapeutics stock was soaring in morning trading; reaching a high today so far of $1.40 per share. However, since the big morning spike, growth seems to be correcting and the company’s stock has fallen to $1.32 per share so far (11:04). Nonetheless, it’s still very clear that unless some major negative news comes out about the company between now and the closing bell, we’re going to see a close in the green today.

CYTX Outlook

Moving forward, I think we’re going to see growth on a long term scale from Cytori Therapeutics. While it’s important to remember that in the small-cap biotech space, we will see a bit of market volatility; it’s also clear that the company is making big moves to get it’s medications in other areas and increase revenue. So, I definitely see this one moving up over the long run.

What Do You Think?

Where do you think CYTX is headed? Let us know in the comments below.

2 3413
Email Hack

Email HackThis morning, I got a bit of a shock. The Federal Trade Commission sent me an email. That’s awesome, the FTC noticed that we’re growing. That being said, thank you to all of our followers and contributors; we absolutely love this community! So, what did the FTC say? Were we in trouble? Did we need to delete an article? Nope! They asked us to spread the word about a couple new videos they’ve created in an attempt to help consumers who are dealing with hacked emails and computers. That being said, how can I say no to the FTC?

OK, Let’s Get Serious For A Minute!

These days, we live our lives in front of computer screens. It’s where we bank, where we shop, where we invest, and for many of us, where we work! Could you imagine trying to get into your email and being locked out; or even worse, what if your computer suddenly didn’t work anymore? Unfortunately, these things happen more often than you think. To give you an idea of how real these threats are, take these stats into account…

  • According to Forbes, in 2013 30,000 websites were hacked daily.
  • According to RT, 47% of adults in the United States experienced a hack in the past year.
  • According to the National Small Business Association, 44% of small businesses have been the victims of hacks.

The list of stats and stats goes on and on. However, there are ways to protect yourself.

Don’t Listen To Me…Listen To The FTC!

New Video #1 – Hacked Email: What To Do – Click Here

New Video #2 – Hijacked Computer: What To Do – Click Here

Micron Technology Stock News

Micron Technology Stock NewsMicron Technology, Inc. (NASDAQ: MU)

Tech investors like myself have been watching Micron Technologies closely as they anticipated the earnings report release yesterday. Well, the earnings report was a hit and the stock is up. Here’s what we learned from the company’s second fiscal quarter earnings report, how the market reacted to the news, and what we can expect to see moving forward from the memory chip maker.

Micron Technology Earnings Report

As mentioned above, the Micron Technology earnings report was a hit. Not only did the company meet expectations, they blew them away! Here are the key points from the report…

  • Earnings Per Share – In the second fiscal quarter of 2015, Micron Technology generated earnings in the amount of $0.78 per share; smashing analyst expectations of $0.73 per share.
  • Revenue Growth – Year over year, revenue grew by 1.5%; clocking in at $4.17 billion. Analysts expected revenue to come in at $4.15 billion.

There We A Couple Of Issues With The MU Report

In the quarter, revenue was down by 9% compared to the quarter before. The company stated that the fall is primarily the result of DRAM unit sale declines and selling price declines for both DRAM and NAND memory units. These issues lead to a gross margin decline to 34%; a number that clocked in at 36% last quarter.

How The Market Reacted To The Report

After hours traders had a ball with the positive news last night; pushing the stock to highs. However, in morning trading today, it seems as though MU has leveled off a bit. Currently (12:33), the stock is trading at $27.21 per share after a gain of 0.29% so far today.

Where MU Stock Will Go Next

While the earnings report beat was positive, there are a couple of major concerns as mentioned above. With declines in sales and price declines in products, the outlook declines as well in my opinion. While I still see short term gains in the future for this one on the positive earnings; I am a bit concerned for the long run.

What Do You Think?

Where do you think MU is headed? Let us know in the comments below!

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 4649
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...